This is a working overview of Tesamorelin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-26 and is reviewed periodically as new material appears.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
"Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes". Cardiovascular Diabetology. 21 (1): 163. doi:10.1186/s12933-022-01601-w. PMC 9400320. PMID 36002856. Patel, Krishna V.; McGuire, Darren K. (2019). "Long-term follow-up of intensive glycaemic control in type 2 diabetes". Nature Reviews Cardiology. 16 (9): 517–518. doi:10.1038/s41569-019-0241-y. PMID 31337880.
Going back more than 350 years, the first landmark description was of general blood circulation by William Harvey in 1628, which formed the anatomical basis for intravenous infusions. Investigations during the following centuries demonstrated solutions containing electrolytes and glucose could be given intravenously. The accumulated knowledge of protein metabolism formed the basis for studies on intravenous nutrition with protein hydrolysates, peptides, and amino acids. Robert Elman's observation in the late 1930s that amino acids in the form of protein hydrolysate could be administered safely was the first major step toward TPN. During the following years, major efforts were made to find methods to prepare infusion solutions with a high energy content and low osmotic pressure. The most realistic alternative seemed to be fat in the form of an emulsion. Many studies of a large number of various fat emulsions were made from the 1920s until the end of the 1950s. However, all of these emulsions caused severe adverse reactions. The first safe fat emulsion, Intralipid, developed by Prof. Arvid Wretlind of the Karolinska Institute, Sweden, was made available for clinical use in 1962. This was the second major step toward TPN. Vitamins, electrolytes, and trace elements were then included in the fat emulsions and in the solutions of amino acids and glucose. Later in the 1960s, Dr. Stanley Dudrick, who as a surgical resident in the University of Pennsylvania, working in the basic science laboratory of Dr.
T-independent type I antigen — Mitogens that induce nonspecific activation of B cells (at smaller doses, they initially appeared specific to particular B cells, suggesting erroneously that this was an antigen-specific process; subsequent investigation proved their nonspecific nature) T-independent type II antigen — Antigens containing multiple repetitive motifs that allow them to crosslink B cell receptors and directly activate the B cells. Bacterial capsule polysaccharides are a common example. Immunodominant antigens – Antigens that dominate (over all others from a pathogen) in their ability to produce an immune response. T cell responses typically are directed against a relatively few immunodominant epitopes, although in some cases (e.g., infection with the malaria pathogen Plasmodium spp.) it is dispersed over a relatively large number of parasite antigens. These are contrasted with immunosubdominant (sometimes referred to just as "subdominant") antigens. Antigen-presenting cells present antigens in the form of peptides on major histocompatibility complexes. All nucleated cells (i.e., all cells except for red blood cells) express MHC class I, which samples peptides from the cytosol, defaulting to presenting self-antigen (unless something foreign ends up in the cytosol or if the cell is capable of cross-presentation). Antigens originating from outside the cell make their way into the endomembrane system via processes like phagocytosis, endocytosis, or macropinocytosis and are loaded onto MHC class II molecules.
Sources: en.wikipedia.org
=== IGF-1 === In December 2012, topical application of IGF-1 in a liposomal vehicle led to thicker and more rapid hair growth in transgenic mice with androgenic alopecia. The study did not show measurable systemic levels or hematopoietic side effects, suggesting potential for use in humans. Low energy radiofrequency irradiation induces IGF-1 in cultured human dermal papilla cells. Adenosine stimulates dermal papillae in vitro to induce IGF-1, along with fibroblast growth factors FGF7, FGF-2 and VEGF. β-catenin transcription increased, which promotes dermal papillae as well. Dietary isoflavones increase IGF production in scalp dermal papillae in transgenic mice. Topical capsaicin also stimulates IGF at hair follicles via release of vanilloid receptor-1, which in turn leads to more CGRP. Ascorbic acid has led to increased IGF expression in vitro.
Ravi Bhushan (born 12 April 1953, in Muzaffarnagar, India) was a Professor of Chemistry at Indian Institute of Technology Roorkee who worked in the areas of natural products chemistry, protein chemistry, and chiral analysis by liquid chromatography.
== Side effects and overdose == Side effects from intra-articular administration can include joint pain, swelling, lameness, and, rarely, infection of the joint. Intramuscular injection can cause dose-dependent inflammation and bleeding, since PSGAG is an analogue of the anticoagulant heparin. In dogs, this may manifest as bleeding from the nose or as bloody stools. The increased risk of bleeding has some advising not to give PSGAG to animals with bleeding disorders, though its only absolute contraindication is hypersensitivity to PSAGs when it is being given intra-articularily. Overdose on PSGAG is quite rare, as the LD50 is over 1000 mg/kg when given intravenously to dogs. Signs of overdose include exacerbated side effects such as joint pain, swelling, and lameness. When dogs received three times the normal dose intramuscularly twice a week for 13 weeks, they had increased liver and kidney weight, as well as microscopic lesions on the liver, kidneys, and lymph nodes. At 11 times the normal dose, they also had increased alanine transferase, cholesterol, and prothrombin time (i.e. coagulation via the extrinsic pathway took longer), and fewer platelets.
Sources: en.wikipedia.org
In Crigler Najjar disease, there is an inherited deficiency of glucuronyl transferase resulting in high concentrations of unconjugated bilirubin appear in the plasma. Furthermore, those affected may develop kernicterus (deposits of pigment in the brain) that can cause nerve degeneration. In Gilbert's syndrome, glucuronyl transferase activity is reduced by approximately 70%, leading to mild accumulation of unconjugated bilirubin in the plasma. At birth, infants don't develop enough ability to conjugate bilirubin. Up to 8% to 11% neonates will develop hyperbilirubinemia in the first week of their lives.
Team Fortress Classic is a 1999 first-person shooter game developed by Valve and published by Sierra Studios. It was originally released in April 1999 as a mod for Valve's 1998 Windows game Half-Life, and is based on Team Fortress, a mod for the 1996 game Quake. In Team Fortress Classic, two teams compete in online multiplayer matches. Players choose one of nine classes, each with different skills. The scenarios include capture the flag, territorial control, and escorting a "VIP" player. Valve hired the developers of the Team Fortress mod to develop Team Fortress Classic. It received generally positive reviews, although the graphics were a point for criticism. In 2000, Valve released a standalone version, Team Fortress 1.5, with new character models, maps and other features. Team Fortress 2 was released in 2007.
HGEGTFTSDV SSYLEGQAAK EFIAWLVKGR HGEGTFTSDV SSYLEGQAAK EFIAWLVKGR (2 copies of modified GLP-1, modifications underlined) DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV KLVNEVTEFA KTCVADESAE (albumin starts at the beginning of this line) NCDKSLHTLF GDKLCTVATL RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGL
=== PMB === PMB (Probability Matrix from Blocks) of 2004 uses the additivity of evolutionary distances to improve on BLOSUM's analysis of the BLOCKS database. The up-to-date 2001 version of BLOCKS was used to generate a new set of BLOSUM matrices. The "observed substitution frequencies" found in these BLOSUM matrices are used to estimate actual substitution frequencies (with higher evolutionary distance, i.e. lower r, some later replacement can mask earlier replacements). PMB thus defines a true evolutionary model like PAM and JTT do. It is not a symmetric matrix.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.